首页 - 股票 - 研报 - 公司研究 - 正文

泰格医药:Near term pressure from COVID-19outbreak won’t hurt long-term growth prospects

来源:招银国际 2020-04-20 00:00:00
关注证券之星官方微博:

Strong earnings growth in 2019. Tigermed reported inline 2019results withattributable net profit surged 78% YoY to RMB842mn which was mainly due to 1)22% YoY revenue growth, 2) RMB278mn one-off investment gains and fair valuegains, and 3) spin-off of Shengtong (晟通) in Feb 2019. Core net profit rose 56%YoY in 2019to RMB658mn. We estimate the organic revenue growth in 2019Ewas around 27% YoY, excluding impact from the Shengtong spin-off. Grossmargin improved 3.4ppts to 46.5% in 2019thanks to the spin-off of low marginlogistics business and improving operating efficiencies. To factor in the impactfrom COVID-19outbreak, we trimmed 2020E/21E net profit forecasts by 17%/11%respectively and cut SOTP-based TP to RMB87.18, implying 56x FY21E P/E.n Short-term impact from COVID-19outbreak. The progress of clinical trialsin China was delayed due to the COVID-19outbreak. However, hospitals inmost regions in China have resumed operation from Mar 2020. We think theoverall impact on Tigermed’s domestic income will be minimal. However,given that the virus outbreak in the US and Europe were more serious than inChina, Tigermed’s overseas orders could face some delays. We noticed thatthe daily increases in infections cases in the US and major European countrieshave peaked recently. Thus, we believe the impact on Tigermed’s overseasbusiness will last in short term.n Strong backlog growth indicates solid demand in high-quality clinicalCRO services. Tigermed recorded RMB4.2bn backlog additions in 2019, up28% YoY while the Company had RMB5.0bn backlogs as of end-2019, up 36%YoY. The number of ongoing clinical trials in China has been increasing fastthanks to encouraging policies on drug innovation and pharma and biotechcompanies’ rising focus on innovative drug development. Tigermedparticipated in the development of 7out of the 13domestic innovative drugsapproved in 2019, demonstrating its leading position in China’s CRO industry.n Global expansion opens up room for long-term growth. Tigermed’ssubsidiary DreamCIS will be listed in KOSDAQ, which will further strengthenthe Company’s presence in South Korea. In Nov 2019, Tigermed announcedto establish a JV with Accerise to provide MRCT services in Japan. Tigermedalso acquired 3.06% stake in EPS, a Japanese CRO company, in Dec 2019.Tigermed may complete its dual-listing in HKEX in 2020E. With sufficientcapital raised overseas, we believe Tigermed will accelerate the acquisitionprocess in global market.





微信
扫描二维码
关注
证券之星微信
APP下载
相关股票:
好投资评级:
好价格评级:
证券之星估值分析提示泰格医药盈利能力良好,未来营收成长性一般。综合基本面各维度看,股价合理。 更多>>
下载证券之星
郑重声明:以上内容与证券之星立场无关。证券之星发布此内容的目的在于传播更多信息,证券之星对其观点、判断保持中立,不保证该内容(包括但不限于文字、数据及图表)全部或者部分内容的准确性、真实性、完整性、有效性、及时性、原创性等。相关内容不对各位读者构成任何投资建议,据此操作,风险自担。股市有风险,投资需谨慎。如对该内容存在异议,或发现违法及不良信息,请发送邮件至jubao@stockstar.com,我们将安排核实处理。
网站导航 | 公司简介 | 法律声明 | 诚聘英才 | 征稿启事 | 联系我们 | 广告服务 | 举报专区
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-